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Abstract
Background Clinically useful marker molecules for the
progression of gastroesophageal reflux disease and Bar-
rett’s esophagus (BE) to esophageal adenocarcinoma
(EAC) are lacking. Many adenocarcinomas and inflam-
matory conditions exhibit increased expression of ADAMs,
‘a disintegrin and metalloproteinases’.
Methods We assessed the expression of five ADAMs (9,
10, 12, 17, 19) in three esophageal cell lines (Het-1A,
OE19, OE33) by RT-PCR and Western blotting, and in
human samples of normal esophagus, esophagitis, BE,
Barrett’s dysplasia, and EAC by RT-PCR, and in selected
samples by immunohistochemistry.
Results EAC patients showed increased mRNA expres-
sion of ADAMs 9, 12, 17 and 19, as compared to controls.
At immunohistochemistry, ADAM9 and ADAM10 pro-
teins were increased in EAC. Patient samples also showed
increased mRNA expression of ADAM12 in esophagitis, of
ADAM9 in BE, and of ADAMs 9, 12 and 19 in Barrett’s
dysplasia, as compared to controls. Two EAC cell lines
showed increased ADAM9 mRNA.
Conclusions ADAM9 expression is increased in EAC. Its
predecessors show increased ADAM9 mRNA expression.
The importance of the alterations in ADAM expression for
the development of EAC, and their use as marker mole-
cules, warrant further studies.
Keywords Esophageal adenocarcinoma 
Gastroesophageal reflux disease  Barrett’s esophagus 
ADAM molecules
Introduction
Esophageal adenocarcinoma (EAC) is associated with a
high overall mortality [1], in spite of the advances in its
treatment. The prevention of EAC by treating its recog-
nised predisposing factor, gastroesophageal reflux disease
(GERD), or its sequel, Barrett’s esophagus (BE), by sur-
gery or medication has not proven effective [2–4]. Thus,
the search for clinically useful markers of progression from
BE to malignancy has been extensive but unsuccessful [5].
As there is no evidence to date of a single decisive
transformation pathway leading to EAC, its development is
likely to be multifactorial. A molecule subfamily of the
metalloproteinases, a disintegrin and metalloproteinases
(ADAMs), has been previously linked to both inflamma-
tion [6] and malignancy [7], and, therefore, was chosen to
be studied in the inflammatory, metaplastic, dysplastic and
carcinoma phases of GERD. ADAMs participate in the
shedding of growth factors and in cellular adhesion [8].
Their composition entails them the capacity for multiple
functions: they consist of eight domains, including a
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metalloproteinase and a disintegrin domain, a transmem-
brane sequence, and a prodomain, the removal of which
activates the metalloproteinase domain [9]. Increased
expression of ADAMs has been found in many cancers [7],
and has been also linked to cancer progression and
aggressiveness [10]. ADAMs are naturally inhibited by the
tissue inhibitors of metalloproteinases (TIMPs) [7], and
oncologic medication targeting them has been developed
[10]. Increased ADAM expression has also been found in
inflammatory bowel disease and Helicobacter pylori gas-
tritis [11, 12]. Multiple substrates of ADAMs, including
transforming growth factor beta (TGF-b) and E-cadherin,
have been shown to have a prognostic impact in EAC,
although with no major individual clinical relevance [13].
ADAM mRNA expression has been found to be increased
in esophago-gastric adenocarcinomas [14]. While defining
the origin of the tumours in gastro-esophageal junction is
difficult, it is important because of the probably differing
etiology. For gastric adenocarcinoma, Helicobacter pylori
infection is a strong risk factor, whereas EAC and its risk
factor BE bear an inverse relationship with this infection
[15].
We, thus, wanted to explore the importance of ADAMs
in the GERD-related esophageal and gastroesophageal
junctional (Siewert 1 and 2) cancers during their develop-
ment process. The expression of five ADAM molecules
(ADAMs 9, 10, 12, 17 and 19) was assessed at mRNA
level, and partly at the protein level. Their expression at
different stages of GERD was compared to that in the distal
esophagus of normal controls, as well as to that in the
proximal esophagus of the GERD and EAC patients. The
expression of ADAMs was also analysed in cell lines of an
esophageal and a gastroesophageal junctional adenocarci-
noma, and from the normal esophagus. ADAM9 expression
was increased in EAC at both the protein and mRNA
levels, and ADAM9 mRNA was increased in BE and
Barrett’s dysplasia.
Materials and methods
The study protocol was approved by the Ethics Committee
of the Department of Surgery, Helsinki University Hospital.
Cell lines and cell culture
Cell lines of Barrett’s adenocarcinoma (OE33), and of
adenocarcinoma of the gastroesophageal junction (OE19),
the authenticity of which has been confirmed [16], were
used. For comparison, Het-1A, a cell line drawn from
normal esophageal tissue transfected with a SV40 large T
antigen, was used. OE33 and OE19 were purchased from
Health Protection Agency Culture Collections (Salisbury,
UK), and Het-1A and the gastric carcinoma cell line NCI-
N87 that served for standardization from LGC Promochem
(Middlesex, UK). The cell lines were cultured in 37 C in
media as follows: OE33, OE19 and NCI-N87 in RPMI
?10 % FBS (fetal bovine serum) (Gibco, Carlsbad, CA),
and Het-1A in BEGMTM Bronchial Epithelial Cell Growth
Medium (Cambrex Bio Science, East Rutherford, NJ).
Patient characteristics
Samples were randomly collected from patients undergo-
ing upper gastrointestinal endoscopy or esophageal surgery
during years 2007–2010, and classified according to the
histology (Table 1). Controls were patients with normal
esophageal mucosa undergoing endoscopy for suspected
upper gastrointestinal pathology. One patient was included
in two different study groups, as first biopsied BE with
mild dysplasia, and transformed later to EAC during fol-
low-up.
Tissue samples
All patients gave a written, informed consent of their
participation. Tissue samples were collected in upper gas-
trointestinal endoscopies, or at surgery due to esophageal
adenocarcinoma or high-grade dysplasia. Two to three
samples from three different locations were drawn for each
patient from both the distal (approx. 2 cm above the gas-
troesophageal junction), and the proximal esophagus (at
approx. 15 cm above the gastroesophageal junction). One
sample was placed in RNAlater (Qiagen, Hilden, Germany)
for RT-PCR, and other samples from the same location
were fast-frozen in liquid nitrogen, or directly placed in
10 % formalin for immunohistochemistry.
Extraction of RNA and proteins
RNA from the cell lines was isolated using the RNeasy
Mini Kit (Qiagen, Germantown, MD) according to the
protocol specified in the Kit. From the tissue samples, RNA
was extracted by the RNeasy Fibrous Tissue Mini Kit from
(Qiagen). Tissues were homogenized in the Thermo Savant
FastPrep (Qbiogene, Carsbad, CA). RNA was then isolated
according to the Kit protocol, except for the double amount
of Buffer RLD and Proteinase K used in tissue homoge-
nization. For all mRNA samples, the DNAse Kit (Qiagen,
Hilden, Germany) was used to eliminate DNA.
Proteins from the cell lines were extracted using a buffer
containing 150 mmol NaCl, 10 mmol Tris–HCl, Tris-Base,
1 mmol EDTA, 1 mmol EGTA. 1 % TritonX-100 and 0.5 %
Np-40 with pH of 7.6. Proteinase inhibitors Roche’s Com-
plete block A (1 tbl/50 ml) and PMSF (phenylmethylsulfonyl
fluoride) were added to the buffer before use.
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Reverse transcription (RT)-PCR
RNA was reversely transcripted to cDNA using the High
Capacity cDNA Archive Kit (Applied Biosystems, Foster
City, CA). RT-PCR was performed, and the amount of
cDNA was quantified, with ABI Prism 7000 Sequence
Detection Software exploiting Taqman technology. Primers
were purchased from Applied Biosystems for ADAM9
(Hs00177638_m1), ADAM10 (Hs00153853_m1),
ADAM12 (Hs01106104_m1), ADAM17 (Hs00234224_
m1), and ADAM19 (Hs00224960_m1). For the cell lines,
RT-PCR for each ADAM was run in triplicate, and for the
tissue samples, each was run in duplicate.
We used two methods for standardization of the RT-
PCR results: The same dilution batch of the cell line NCI-
N87 cDNA was run in every plate to count for plate to plate
variations. The expression of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) in cell lines, along with that of
beta-actin (ACTB) in the tissue samples, was measured for
each specimen and used for correction of the ADAM
expression.
Western blotting
To quantify protein content of cell lines, we used the
Quant-it kit (Invitrogen, Eugene, OR) with fluorescence
plate reader (Wallac 1420, Perkin-Elmer, Turku, Finland).
Extracted proteins were separated by SDS-electrophoresis
on 10 % polyacrylamide gel, and transferred to a nitro-
cellulose membrane (Bio-Rad, Hercules, CA). Odyssey
blocking buffer (Li-Cor, Lincoln, NE) was used for
blocking and antibody dilutions. To detect ADAMs, the
membrane was incubated overnight with primary antibod-
ies (Online Resource 1) in dilutions 1.0 lg/ml. After
incubating with fluorescent-labelled secondary antibodies
(dilution 1:15 000) (Online Resource 1), the signal was
measured with Odyssey infrared scanner (Li-Cor) and
analysed with Odyssey software (v2.1). The GAPDH
expression served for standardisation.
Immunohistochemistry
For immunohistochemistry, 6 controls, 3 patients with
severe esophagitis, 3 with non-dysplastic BE, 5 with dys-
plastic BE, and 7 with esophageal adenocarcinoma were
selected as the most representative samples, irrespective of
their mRNA expression. Immunohistochemistry was per-
formed on formalin-fixed, paraffin-embedded tissue sam-
ples. Antigen retrieval was performed by heating the
glasses in 0.01 M Na-citrate buffer, at pH 6 and tempera-
ture of 98 C for 20 min. For blocking, Normal Horse
Serum 2.5 % (ImmPRESSTM Reagent Kit Universal Anti-
Mouse/rabbit Ig, MP-7500, Vector Laboratories,T
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Burlingame, CA) was used. Glasses were then incubated
with primary antibodies overnight at 4 C. Antibodies were
targeting ADAM9 (AB19024, dilution 1:400, Millipore
(Billerica, MA)), ADAM10 (AB936, 1:750, R&D Systems,
Minneapolis, MN), ADAM12 (LS-B2756, 1:2000, LifeS-
panBioSciences (Seattle, WA)), ADAM17, HPA010738-
100 UL, 1:50, Sigma-Aldrich (St.Louis, MO)), and
ADAM19 (sc25988, 1:200, Santa Cruz Biotechnology,
Dallas, TX). After that, slides were soaked with 0.75 %
H2O2 for 30 min, and then incubated with peroxidase-
conjugated secondary antibodies: ImmPRESSTM Reagent
Kit peroxidase, Anti-Goat Ig and Universal Anti-Mouse/
Rabbit Ig (Vector Laboratories, Burlingame, CA). DAB
(3,30-Diaminobenzidine)was used for visualizing the per-
oxidase reaction. The slides were coated with ClarionTM
Mounting Medium (C0487-100 ml, Sigma-Aldrich, Inc,
St.Louis, MO).
The IHC slides were analysed by two of the researchers
(LK and TK), and the cellular localisation of ADAMs was
assessed. ADAM expression in each sample was graded
from 0 to 3 (0 = no staining, 1 = mild staining,
2 = medium staining, 3 = strong staining) based on the
intensity and extensity of the staining.
Statistical analysis
Statistical analysis was conducted with SPSS Statistics 22
(SPSS Inc., Chicago, IL). Results are given as mean and
standard error of mean (SEM) range, or median and range.
Normality of the distributions was assessed with Kol-
mogorov–Smirnov test. Parametric tests were used for the
normally distributed variables, and non-parametric tests
otherwise. The unpaired (patients to controls, cell lines) or
paired (intrinsic proximal controls) Student’s t test was
used for normally distributed variables, whereas the Mann–
Whitney U test or the Wilcoxon signed-rank test was used
for the non-normal data. To compare the different stages of
GERD, ANOVA with Dunnett’s test to correct for multiple
comparisons were used as parametric tests and the Krus-
kall-Wallis and Dunn’s test (to correct for the multiple
comparisons) as non-parametric tests. The Jonckheere-
Terpstra test was used to evaluate ADAM expression
during the control–esophagitis–BE–BE with dysplasia–
adenocarcinoma sequence. p value B0.05 was considered
statistically significant, and two-tailed tests were used.
Results
ADAM mRNA expression in cell lines
The expression of ADAM9 mRNA was increased in both
the Barrett’s adenocarcinoma cell line OE33, and the
gastro-esophageal junctional adenocarcinoma cell line
OE19 as compared to Het-1A (Fig. 1). For ADAM10, its
mRNA expression did not differ in OE33, but decreased in
OE19. The mRNA expressions of ADAM12 and ADAM19
were decreased in both OE33 and OE19. The expression of
ADAM17 mRNA was increased in OE33, but did not differ
in OE19.
ADAM protein expression in cell lines
The expression of the precursor and mature forms of
ADAM proteins was analysed and shown for ADAMs 9
and 10 in Fig. 2.
For ADAM9, two precursor forms (at 110 kD and 100
kD), and two mature forms (at 80 kD and 75 kD) were
observed. The expression the mature form at 80 kD was
decreased in OE33 (p = 0.0031) and OE19 (p = 0.0026),
and that of the mature form at 75 kD was increased in
OE33 (p\ 0.001) (Fig. 2a). For ADAM10, the expression
of both the precursor form (at 80 kd) and the mature form
(at 60 kD) were increased in OE33 (precursor form,
p = 0.0011; mature form, p\ 0.001) and OE19 (precursor
form, p = 0.0095; mature form, p\ 0.001), relative to the
squamous control Het-1A (Fig. 2b). For ADAM12, only a
precursor form was detected, and no change in its expres-
sion was seen (data not shown). For ADAM17, both a
precursor form at 110 kD and a mature form ad 90 kD were
detected, with no change in their expression, however (data
not shown). For ADAM19, only small fragments of the
protein were seen (data not shown).
ADAM mRNA expression in patient samples
The ADAM9 mRNA expression in distal esophagus dif-
fered between groups (p = 0.002), and was increased in
BE (p = 0.004), BE with dysplasia (p = 0.014), and in
esophageal adenocarcinoma (p = 0.043), relative to
Fig. 1 ADAM mRNA expression in esophageal cell lines relative to
expression in Het-1A, and corrected with GAPDH-expression. Stars
indicate t test comparisons with significant difference (p B 0.05)
between the cell line in question, and Het-1A. Error bars represent
the standard error of mean. AC adenocarcinoma, GEJ gastro-
esophageal junction
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controls (Fig. 3a). The trend test showed a rising trend
along the progressive stages of GERD from the control
group to EAC (p = 0.001). When compared to proximal
intrinsic controls, esophagitis (p = 0.015), BE (p\ 0.001)
and EAC (p = 0.018) showed increased ADAM9
expression.
The ADAM10 mRNA expression in distal esophagus
varied between groups (p = 0.007), but the difference
was not statistically significant for any single group
(Fig. 3b). There was neither rising nor declining trend in
the different stages of GERD. When compared to proxi-
mal intrinsic controls, ADAM10 mRNA expression in BE
was higher than in these patients’ proximal esophagus
(p = 0.001).
The ADAM12 mRNA expression in distal esophagus
differed between groups (p\ 0.001). It was increased in
esophagitis (p = 0.038), BE with dysplasia (p = 0.001),
and EAC (p\ 0.001), relative to normal controls (Fig. 3c).
In the trend test, there was a rising trend in ADAM12
expression (p\ 0.001). In comparison to the proximal
intrinsic controls, dysplastic BE (p = 0.039) and EAC
(p = 0.001) showed increased ADAM12 expression.
The ADAM17 mRNA expression in distal esophagus,
also, differed between groups (p = 0.001). It was increased
in EAC (p = 0.004) (Fig. 3d). Neither rising nor declining
trend during the GERD sequence was noted, and there were
no differences relative to the proximal intrinsic controls.
The ADAM19 mRNA expression in distal esophagus
differed between groups (p = 0.002). ADAM19 mRNA
was increased in dysplastic BE (p = 0.044) and in EAC
(p = 0.001) (Fig. 3e). The trend test showed a rising trend
in ADAM19 expression (p\ 0.001). When compared to
proximal intrinsic controls, esophagitis (p\ 0.001) and
non-dysplastic BE (p = 0.025) showed increased
ADAM19 expression.
Correlation with patient characteristics
The mRNA expression of ADAMs in the distal esophagus
did not differ between the groups with or without neoad-
juvant treatment (data not shown). Their expression was
also not associated with cancer differentiation (good,
moderate, poor) or dysplasia grade (mild, severe) (data no
shown). ADAM9 expression was increased in Siewert1
cancers as compared to Siewert2 cancers (shown in Online
Resource 2). ADAM12 was increasingly expressed in
severe esophagitis as compared to mild esophagitis, as
were also ADAM17 and ADAM19 (shown in Online
Resource 2).
ADAM protein expression in patient samples
Normal esophageal squamous epithelium did not show
distinct expression of ADAM 9, 10, or 17 proteins.
ADAM12 was rarely seen in apically centred cytoplasmic
granules. Only ADAM19 was mildly to moderately
expressed in the cytoplasm of esophageal squamous cells.
At whole, ADAM expression was centred in the glandular
cells of the metaplastic/dysplastic esophageal epithelium,
and was localized mostly in the cytoplasm but in EAC also
occasionally in the nucleus.
ADAM9 was expressed in BE (Fig. 4c) and Barrett’s
dysplasia, with no increased staining relative to controls
(for dysplasia, p = 0.077, median 1, range 1–1 in dysplasia
vs. median 0.5, range 0–1 in controls) or from BE to
dysplasia. EAC showed increased ADAM9 protein
expression relative to controls (median 1, range 1–2 in
EAC vs. median 0.5, range 0–1 in controls, p = 0.026)
(Fig. 4a, d). ADAM9 was not differently expressed in
esophagitis (Fig. 4b).
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Fig. 2 Protein expression of ADAM9 a and ADAM10 b in
esophageal cell lines by western blotting. A representative western
blot, and the corresponding standardisation blot of GAPDH from the
same nitrocellulose membrane, are shown below the densitometric
results (N = 4–6). T test comparisons to Het-1A with significant
difference (p B 0.05) are indicated with stars. Error bars represent
SEM (standard error of mean). AC adenocarcinoma, GEJ gastro-
esophageal junction
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Fig. 3 ADAM mRNA expression in patient samples of different
stages of GERD in both the distal and proximal esophagus. Error bars
represent the standard error of mean. Stars indicate ANOVA/
Dunnett’s or Kruskal–Wallis/Dunn’s test comparisons with significant
difference (p B 0.05) between the patient group and controls, and hat
symbol indicates paired t test or Wilcoxon signed rank test
comparisons with significant difference (p B 0.05) between the distal
and proximal samples of the same patient group. Values represent
relative expression as compared to the expression in NCI-N87 cell
line, corrected for the mean of GAPDH and beta actin expression in
the same samples. ADAM9 (a) ADAM10 (b) ADAM12 (c) ADAM17
(d) ADAM19 (e)
Fig. 4 ADAM9 protein expression in normal squamous mucosa of
distal esophagus (original magnification 9100) (a), in esophagitis
(9200) (b), in Barrett’s esophagus (9100) (c), and in esophageal
adenocarcinoma (9100) (d). ADAM10 expression in normal
squamous mucosa of distal esophagus (9200) (e), in esophagitis
(9200) (f), in Barrett’s esophagus (9100) (g) and in esophageal
adenocarcinoma (940) (h)
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ADAM10 expression showed a tendency for basal
localisation in BE, while in Barrett’s dysplasia its expres-
sion was more evenly distributed. In EAC, ADAM10 was
increasingly expressed relative to controls (Fig. 4e, h)
(median 2, range 1–2 in EAC vs. median 1, range 0–1 in
controls, p = 0.021), while for dysplasia there was no
increase (median 1, range 1–2 in dysplasia vs. median 1,
range 0–1 in controls, p = 0.061), and neither for BE
(Fig. 4g). ADAM10 was not differently expressed in
esophagitis (Fig. 4f).
The significant increase of ADAM12 mRNA in severe
esophagitis was not reflected at the protein level. Statisti-
cally, ADAM12 expression did not differ from normal
esophageal squamous epithelium at any stage of GERD.
ADAM17 was increasingly expressed in BE relative to
normal controls (median 2, range 2–2 in BE vs. median 0.5,
range 0–1 in controls, p = 0.024), while for Barrett’s
dysplasia or EAC there was no difference in the expression
relative to controls.
ADAM19 was expressed at all stages of GERD (in-
cluding severe esophagitis), with a tendency for transfor-
mation from basally centred staining in BE to apically
centred staining in EAC. Statistically, however, the
ADAM19 expression in BE/dysplasia/EAC did not differ
from the controls.
Discussion
To our knowledge, this is the first study to examine the
ADAM expression in the various phases of GERD pre-
ceding cancer, and in EAC also at the protein level.
ADAM9 was increased in EAC, and in BE and BE with
dysplasia at mRNA level. Other ADAMs studied showed
alterations as well, and may participate in the complex
network of interactions leading to EAC development.
In EAC, both ADAM9 mRNA and protein expression
were elevated. Also in the cancer cell lines, ADAM9
mRNA was elevated, and in the Barrett’s adenocarcinoma
cell line, ADAM9 protein was elevated. The demonstrated
functions of ADAM9 in cancer include promoting cellular
adhesion and invasion, as well as interaction with integrins
[7]. It can bind to the a6b4-integrin, the a6-subunit of
which is upregulated in EAC [7, 17]. ADAM9 has been
found increased e.g. in gastric and prostate cancer, and in
pancreatic ductal adenocarcinoma [18–20]. There is pre-
liminary evidence of ADAM9 being involved in invasion/
metastasis [21–23]. Oxidative stress, which is also
increased in EAC and its predecessors [24], induces the
expression of ADAM9 [20], which also contributes to the
cellular invasion induced by oxidative stress [25]. Given
the potential contribution of ADAM9 for the cancer
metastasising, and the availability of an inhibitor [7], it
remains an interesting candidate for further studies
assessing its function in GERD and EAC.
ADAM10 protein but not mRNA expression was
increased in EAC both in the cell lines and in human
samples. This might be caused by some posttranscriptional
or posttranslational modulation leading to e.g. increased
translation of mRNA, or decreased degradation of the
protein. As shown before for ADAM17, posttranscriptional
mechanisms may alter ADAM protein expression without a
change in mRNA level by altering the protein half-life
[26]. Previously, however, an increase in ADAM10 mRNA
has been found in esophago-gastric carcinomas [14].
ADAM10 expression has been linked to many human
cancers [7]. Possible mechanisms for promoting carcino-
genesis in EAC include its ability to cleave tumour necrosis
factor alpha (TNF-a) [27], increased along the meta-
plasia—dysplasia—carcinoma—sequence [28], and
E-cadherin [29], leading to increased free ß-catenin levels,
and thereby increased expression of the proto-oncogene
C-myc, also found upregulated in Barrett’s adenocarci-
noma [28, 30]. It might also act by cleaving the adhesion
molecule CD44 [7], also shown to be associated with EAC
[17].
In human samples, ADAM12 mRNA was increased in
esophagitis, BE with dysplasia, and in EAC. ADAM19
showed a similar expression profile, except for that in
esophagitis and BE it was increased only relative to
intrinsic controls. These elevations were not, however, seen
at the protein level. It is possible that in these tissues the
prevailing form of these ADAMs was not captured by our
IHC protocol. ADAM12 may exist as a membrane-an-
chored long form, or as a soluble secreted form [31]. As
ADAM12 and ADAM19 mRNA were highly expressed in
esophagitis, their increased expression in EAC might
reflect the inflammatory changes seen, and possibly of
importance for the development of a malignancy, such as
EAC [32, 33]. Our results are in accordance with the pre-
vious study of esophago-gastric adenocarcinomas [14].
ADAM12 and ADAM19 expression have been linked to
both inflammatory diseases and cancer [7, 11, 31, 34, 35].
ADAM17 mRNA, but not protein, was increased in
EAC in human samples, and in the Barrett’s adenocarci-
noma cell line OE-33. IHC may not have captured the
relatively small increase in mRNA. Tumours also showed
marked heterogeneity in the expression of ADAM17 pro-
tein. Previously, ADAM17 mRNA has been found
increased in esophago-gastric adenocarcinomas [14]. This
molecule is one of the most studied ADAM-molecules and
is upregulated in many human cancers [7]. It cleaves TNF-
a, and also TGF-b, both cytokines of possible importance
in EAC [7, 13, 36].
We compared the ADAM expression in GERD and EAC
to both normal controls and to the proximal unaffected
64 Clin Transl Oncol (2017) 19:58–66
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mucosa of the patients. The previous study of esophago-
gastric adenocarcinomas compared the ADAM expression
in cancer to ‘‘peri-tumoural normal tissue’’ [14]. We used
statistical correction for the multiple comparisons problem,
which may have affected our results in comparison to
studies without these corrective methods. Our results were,
however, mostly in accordance with the previous study
showing increased ADAM mRNA expression in esophago-
gastric adenocarcinomas [14].
A limitation of our study was the relatively small
number of samples, especially in the preliminary charac-
terisation of ADAM expression at the tissue level by IHC.
The elevated ADAM mRNA levels were not always seen at
the protein level. This may be at least partly due to
ADAMs being subjects to significant post-transcriptional
and post-translational regulation [8]. This kind of modu-
lation, leading possibly to altered levels of specific iso-
forms, altered function, or altered localisation, may even be
an important regulatory mechanism controlling the cellular
and inter-cellular actions of ADAMs.
The major disparities between ADAM expression in the
cell lines studied and the human samples are not surprising,
given the individual nature of molecule expression in each
cancer and heterogeneity across each tumour [37]. In
human samples, a factor likely to affect the molecular
expression is the stroma and its interactions with the cancer
cells [38]. With the small number of samples, neoadjuvant
treatment did not affect ADAM expression. Our patients
were a little older than the controls, and there was a male
predominance in patients in contrast to the male proportion
of only 35 % in the controls. This is likely to mostly reflect
the age and gender as known risk factors of BE and EAC
[39]. To our knowledge, no reports of age- or gender-de-
pendent differences in ADAM expression in the adult have
been reported, but a possible bias cannot be excluded.
We have shown that the expression of this multifunc-
tional ADAM protein group is altered in EAC and during
its development. ADAMs are linked to inflammatory pro-
cesses and to many molecules already shown to be dys-
regulated along the development of EAC. Even a minor
modification in the expression of regulatory molecules,
such as ADAMs, may have a significant impact. Future
studies with more samples, data on protein levels, associ-
ation with prognostic factors and fate, and functional
assays, are needed to define the role of ADAMs in eso-
phageal carcinogenesis.
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